Your browser doesn't support javascript.
loading
Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey.
Jovenaux, Ludovic; Cautela, Jennifer; Resseguier, Noemie; Pibarot, Michele; Taouqi, Myriam; Orabona, Morgane; Pinto, Johan; Peyrol, Michael; Barraud, Jeremie; Laine, Marc; Bonello, Laurent; Paganelli, Franck; Barlesi, Fabrice; Thuny, Franck.
Afiliación
  • Jovenaux L; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
  • Cautela J; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
  • Resseguier N; Aix-Marseille University, Department of Public Health, Research Unit EA 3279, France.
  • Pibarot M; Assistance Publique - Hôpitaux de Marseille (AP-HM), ONCO-PACA-CORSE Oncology Regional Network, France.
  • Taouqi M; Assistance Publique - Hôpitaux de Marseille (AP-HM), ONCO-PACA-CORSE Oncology Regional Network, France.
  • Orabona M; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
  • Pinto J; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
  • Peyrol M; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
  • Barraud J; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
  • Laine M; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
  • Bonello L; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
  • Paganelli F; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
  • Barlesi F; Groupe Méditerranéen de Cardio-Oncologie (gMEDICO), France; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Oncosaftey Network of the Early Phases Cancer Trials Center (CLIP(2)), France; Aix-Marseille University, Multidisciplinary Oncology & Therapeutic Innovations
  • Thuny F; Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille (AP-HM), Mediterranean University Cardio-Oncology Center (MEDI-CO Center), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Hôpital Nord, France; Mediterranean Association for Research and Studies in Ca
Int J Cardiol ; 241: 387-392, 2017 Aug 15.
Article en En | MEDLINE | ID: mdl-28365180
ABSTRACT

BACKGROUND:

Cardiovascular toxicity has become a challenging issue during cancer therapy. Nonetheless, there is a lack of consensual guidelines for their management. We aimed to determine the current practices of oncologists regarding cardiovascular toxicity related to anthracyclines, trastuzumab and angiogenic inhibitors and to gather their opinions on the development of cardio-oncology programs.

METHODS:

A cross-sectional declarative study was submitted to French oncologists in the form of an individual, structured questionnaire.

RESULTS:

A total of 303 oncologists responded to the survey. Ninety-nine percent of oncologists prescribed cardiotoxic therapies, including anthracyclines (83%), trastuzumab (51%) and other angiogenic inhibitors (64%). The method adopted for managing cardiovascular toxicity was based on guidelines from expert oncology societies for only 35% of oncologists. None was aware of recommendations from expert cardiology societies. Prescription of pre-, peri- and post-therapy cardiovascular assessment was inconsistent and significantly less frequent for all classes of angiogenic inhibitors than for anthracyclines and trastuzumab (P<0.0001). Relative to pre-therapy assessment, post-therapy assessment was prescribed significantly less often for all cancer therapies (P<0.0001). Attitudes regarding the onset of left ventricular dysfunction were much more inconsistent when angiogenic inhibitors were involved. Additionally, the management of hypertension and QT prolongation was also inconsistent. Finally, 88% of oncologists supported projects of cardio-oncology programs development.

CONCLUSIONS:

Practices of oncologists are disparate in the field of cardiovascular toxicity. This finding underlines the complexity of managing many different situations and the need for distribution of formal guidelines from oncology and cardiology expert societies. The development of personalized cardio-oncology programs seems essential.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encuestas y Cuestionarios / Manejo de la Enfermedad / Cardiotoxinas / Cardiólogos / Neoplasias / Antineoplásicos Tipo de estudio: Guideline / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Límite: Humans Idioma: En Revista: Int J Cardiol Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encuestas y Cuestionarios / Manejo de la Enfermedad / Cardiotoxinas / Cardiólogos / Neoplasias / Antineoplásicos Tipo de estudio: Guideline / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Límite: Humans Idioma: En Revista: Int J Cardiol Año: 2017 Tipo del documento: Article
...